– USA, CA – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the additions to its Board of Directors of Dr. Nancy Andrews, M.D., Ph.D., Dr. Catherine Angell Sohn, Pharm.D., and Dan Spiegelman.
The company also announced that Atul Dandekar, a successful business leader with nearly 25 years of pharmaceutical industry experience, joined as chief strategy officer.
“We have been making significant progress at Maze, leveraging our proprietary COMPASS platform to identify and advance a very exciting pipeline of therapeutic candidates based on new, pivotal insights into genetic drivers of both rare and common diseases,” said CEO, Dr. Jason Coloma. “Our COMPASS platform has the potential to lead us to establish a very broad pipeline that we will advance internally or through partnerships, and Atul’s guidance on our execution strategy will be critical. We are very excited to have him on board to help advance our precision therapies toward clinical development and ultimately to patients.”
“Maze has built an impressive portfolio of potential therapeutic candidates, all informed by our curated COMPASS platform that combines human genetic data, functional genomic tools, and data science technology to improve drug development efficiencies,” said Mr. Dandekar. “Since I began following the Maze story, I have been inspired by the broad potential of the platform and continue to be impressed with the progress the company has made in such a short period of time. With our ability to elucidate precision medicines based on novel genetic insights, we have a significant opportunity to shift the future of how specific individuals are treated for their disease.”
Board Chairman, Dr. Charles Homcy who is a Third Rock Ventures partner added, “Despite the many recent advancements in genetics, the ability to discern which elements are critical for patient therapies, and which are not, has proven challenging. Maze and the COMPASS platform offer an incredible opportunity to propel genetic medicine forward toward clinical application through new, actionable insights into human genetics and biology. As we grow and advance as a company, it is key that we have the support of a dedicated and passionate board of directors, and as such, are thrilled to welcome Nancy, Catherine, and Dan to the Maze board. Their diverse backgrounds spanning academia and clinical practice, as well as finance, business, and drug and product development strategy, will be highly valuable to Maze going forward.”
About Dr. Nancy Andrews
Nancy Andrews, M.D., Ph.D., has extensive experience as a physician, scientist, professor, and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke University School of Medicine. Dr. Andrews is currently Dean Emerita of the School of Medicine, Vice Chancellor Emerita for academic affairs, and professor of pediatrics, pharmacology, and cancer biology at Duke University. She also chairs the board of the American Academy of Arts and Sciences and is credited with conducting research that led to advances in understanding iron biology and iron diseases. Dr. Andrews also sits on the boards of directors of Novartis and Charles River Laboratories and is a member of the Executive Committee of the MIT Corporation and the Council of the National Academy of Sciences.
Dr. Andrews holds an M.D. from Harvard University, a Ph.D. in biology from Massachusetts Institute of Technology, and an M.S. and B.S. in molecular biophysics and biochemistry from Yale University.
About Dr. Catherine Sohn
Catherine Sohn, Pharm.D., is an experienced biopharmaceutical executive with expertise in strategy, strategic product development, business development, and commercialization of new medicines. Dr. Sohn currently serves as chairman of the board of BioEclipse Therapeutics and as a director for Jazz Pharmaceuticals plc, Rubius Therapeutics, Axcella Health, and Landec Corp. She was formerly SVP, world business development at GlaxoSmithKline Consumer Healthcare, and before that, she was VP of worldwide strategic product development for the cardiovascular, pulmonary, and metabolic therapeutic areas at SmithKline Beecham Pharmaceuticals.
Dr. Sohn received a Doctor of Pharmacy degree from the University of California, San Francisco, and a Certificate of Professional Development from the Wharton School at the University of Pennsylvania. She also currently serves as an adjunct professor at UCSF and teaches in the American Course on Drug Development and Regulatory Science.
About Dan Spiegelman
Dan Spiegelman has served as a CFO in several diversified biotechnology companies spanning 30 years. He was most recently executive vice president and chief financial officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on the development of first-in-class and best-in-class therapeutics for rare genetic diseases. Earlier, he was a financial consultant for biotechnology companies and served in executive financial positions at CV Therapeutics and Genentech. Mr. Spiegelman currently serves on the boards of Tizona Therapeutics, Inc., Myriad Genetics, Spruce Biosciences, Opthea Limited, and Jiya Acquisition Corp. He has previously served on several public and private biotech company boards.
Mr. Spiegelman received an MBA and a B.A. in economics from Stanford University.
About Atul Dandekar
Atul Dandekar brings extensive experience leading strategy, operations, clinical development, and commercialization for biotech and pharmaceutical companies. Most recently, he was vice president, global franchise head for ophthalmology at Genentech and Roche, where he was responsible for leading the global ophthalmology business. He led the development of the global Roche ophthalmology strategy and led the ophthalmology cross-Roche team that helped develop faricimab, PDS with ranibizumab, and an industry-leading retina pipeline. Before this role, he led the Phase 3 development programs for faricimab and lampalizumab. Before joining Genentech in 2014, Mr. Dandekar was the senior global program head in neuroscience at Novartis. During his 16-year tenure at Novartis, Mr. Dandekar held roles of increasing responsibility in diverse areas of clinical development, disease area strategy, and marketing in India, Australia, and Switzerland. Mr. Dandekar is an advisor for the SPARK program at Stanford and a reviewer for Cures within Reach.
Mr. Dandekar holds degrees in medicine and management from Mumbai University and a master’s in marketing management from Monash University.
About Maze Therapeutics
Maze Therapeutics is focused on translating genetic insights into new precision medicines for rare diseases and mechanistically defined subsets of common diseases. Maze has developed the COMPASS platform, a proprietary, purpose-built platform that combines human genetic data, functional genomic tools, and data science technology to map novel connections between known genes and their influence on susceptibility, the timing of onset, and rate of disease progression. Using COMPASS, Maze is building a broad portfolio, including wholly-owned programs targeting Pompe disease, chronic kidney disease, and amyotrophic lateral sclerosis, as well as partnered programs in cardiovascular and ophthalmic diseases. Maze is based in South San Francisco.
For more information: https://mazetx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.